SG11201908059YA - Nucleic acid derivative having immunostimulatory activity - Google Patents

Nucleic acid derivative having immunostimulatory activity

Info

Publication number
SG11201908059YA
SG11201908059YA SG11201908059YA SG11201908059YA SG 11201908059Y A SG11201908059Y A SG 11201908059YA SG 11201908059Y A SG11201908059Y A SG 11201908059YA SG 11201908059Y A SG11201908059Y A SG 11201908059YA
Authority
SG
Singapore
Prior art keywords
nucleic acid
acid derivative
strand
immunostimulatory activity
nucleotides
Prior art date
Application number
Inventor
Akira Kugimiya
Tetsuya Tanino
Mitsuaki Sekiguchi
Yasunori Mitsuoka
Norikazu Kuroda
Jun Nakamura
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of SG11201908059YA publication Critical patent/SG11201908059YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Abstract

The purpose of the present invention is to provide double-stranded oligonucleotides comprising the CpG oligonucleotide mentioned below, as a nucleic acid derivative having an immunostimulatory activity. An adjuvant comprising a double-stranded oligonucleotide, wherein a first strand is a CpG oligonucleotide consisting of 8 to 50 nucleotides, a second strand is an oligonucleotide consisting of 8 to 60 nucleotides and comprising a sequence capable of hybridizing with the first strand, and a lipid 10 binds to the second strand through a linker. 179
SG11201908059Y 2017-03-29 2017-03-29 Nucleic acid derivative having immunostimulatory activity SG11201908059YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2017/013025 WO2018179172A1 (en) 2017-03-29 2017-03-29 Nucleic acid derivative having immunostimulatory activity

Publications (1)

Publication Number Publication Date
SG11201908059YA true SG11201908059YA (en) 2019-10-30

Family

ID=63674710

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908059Y SG11201908059YA (en) 2017-03-29 2017-03-29 Nucleic acid derivative having immunostimulatory activity

Country Status (7)

Country Link
JP (1) JP6611298B2 (en)
BR (1) BR112019019177B8 (en)
IL (1) IL268983B1 (en)
MY (1) MY186779A (en)
PH (1) PH12019502063A1 (en)
SG (1) SG11201908059YA (en)
WO (1) WO2018179172A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111601900A (en) * 2017-11-02 2020-08-28 詹森生物制药有限公司 Oligonucleotide constructs and uses thereof
EP3978024A4 (en) 2019-06-03 2023-08-30 Shionogi & Co., Ltd Production method for bifurcated lipid-linked oligonucleotide, and intermediate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60017259T2 (en) * 1999-08-13 2005-12-08 Hybridon, Inc., Cambridge Modulation of CPG oligonucleotide-mediated immune stimulation by positional modification of nucleosides
AU2003203079B9 (en) * 2002-02-04 2009-01-15 Oncothyreon Inc. Immunostimulatory, covalently lipidated oligonucleotides
GB0605247D0 (en) * 2006-03-15 2006-04-26 Chiron Srl Compositions and methods for immunisation
CN102202689A (en) * 2008-08-28 2011-09-28 葛兰素史密丝克莱恩生物有限公司 Vaccine
AU2009325950B2 (en) * 2008-12-09 2013-03-07 Pfizer Vaccines Llc IgE CH3 peptide vaccine
US9107904B2 (en) * 2012-04-05 2015-08-18 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
WO2015105083A1 (en) * 2014-01-07 2015-07-16 塩野義製薬株式会社 Double-stranded oligonucleotide containing antisense oligonucleotide and sugar derivative

Also Published As

Publication number Publication date
WO2018179172A1 (en) 2018-10-04
BR112019019177B1 (en) 2021-05-11
BR112019019177B8 (en) 2022-09-13
IL268983A (en) 2019-10-31
JP6611298B2 (en) 2019-11-27
BR112019019177A2 (en) 2020-04-14
MY186779A (en) 2021-08-19
JPWO2018179172A1 (en) 2020-02-06
PH12019502063A1 (en) 2020-09-28
IL268983B1 (en) 2024-03-01

Similar Documents

Publication Publication Date Title
MX2018002998A (en) Nucleic acid derivative having immunostimulatory activity.
CY1123289T1 (en) OLIGONUCLEOTIDE COMPOUNDS FOR TARGETING HUNTINGTIN mRNA
JP2015142558A5 (en)
WO2016106401A3 (en) Rna agents for p21 gene modulation
MX2010004452A (en) Lipid-modified double-stranded rna having potent rna interference effect.
WO2018041973A9 (en) Chemically modified single-stranded rna-editing oligonucleotides
WO2016140726A3 (en) Triggered assembly of metafluorophores
EA201791820A1 (en) OLIGONUCLEOTIC THERAPY OF CONGENITAL AMAUROSIS LEBER
SG11201806372UA (en) Nucleic acid conjugate
NZ563845A (en) RNAi sequences against the Influenza A segment 1 PB2 gene and uses thereof as anti-viral therapeutic
BR112015024764A2 (en) modified tgf-beta oligonucleotides
BR112013005872A2 (en) compounds, pharmaceutical composition and their uses
MX344972B (en) Immunostimulatory oligonucleotides.
AU2014219019A8 (en) Short interfering nucleic acid (siNA) molecules containing a 2' internucleoside linkage
SG10201705285SA (en) Antisense oligonucleotides
WO2013155204A3 (en) Compositions and methods for inhibiting expression of the alas1 gene
MX2020012133A (en) Complex containing oligonucleotide having immunopotentiating activity and use thereof.
AR100946A1 (en) COMPOSITIONS AND METHODS TO REGULATE GENE EXPRESSION THROUGH RNA INTERFERENCE
MY196912A (en) Short pendant arm linkers for nucleotides in sequencing applications
EA201791986A1 (en) Oligonucleotides, corresponding to exon 73 of the COL7A1 gene, for the therapy of bulletic epidermolysis
ES2651147T3 (en) Oligonucleotides to modulate gene expression and uses thereof
WO2022084331A3 (en) Novel ligands for asialoglycoprotein receptor
PH12019502063A1 (en) Nucleic acid derivative having immunostimulatory activity
PE20211238A1 (en) ANTI-SENSE TREATMENT OF ANGELMAN SYNDROME
WO2017007886A3 (en) Compositions for inhibiting dux4 gene expression and uses thereof